Apimeds Pharmaceuticals US (APUS) EPS (Basic) (2024 - 2026)

Apimeds Pharmaceuticals US (APUS) has reported EPS (Basic) for 3 consecutive years, with -$5.53 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EPS (Basic) fell 114.75% year-over-year to -$5.53; the trailing twelve-month figure through Jun 2026 stood at -$12.35 (down 244.5% YoY), and the FY2025 full-year result was -$11.11, down 699.56% from the prior year.
• EPS (Basic) rose to -$5.53 in Q2 2026 per APUS's latest filing, from -$6.63 in the prior quarter.
• Across five years, EPS (Basic) topped out at -$0.38 in Q1 2024 and bottomed at -$6.63 in Q4 2025.
• Historically, EPS (Basic) has averaged -$2.05 across 3 years, with a median of -$0.57 in 2024.
• The widest YoY moves for EPS (Basic): up 35.73% in 2025, down 1582.72% in 2025.
• Over 3 years, EPS (Basic) stood at -$0.39 in 2024, then slumped by 1582.72% to -$6.63 in 2025, then grew by 16.6% to -$5.53 in 2026.
• According to Business Quant data, EPS (Basic) over the past three periods registered -$5.53, -$6.63, and -$1.43 for Q2 2026, Q4 2025, and Q3 2025 respectively.